Accelerate Diagnostics Stock Price, News & Analysis

Accelerate Diagnostics, Inc. (AXDX) is an in vitro diagnostics company that develops and commercializes systems aimed at addressing the global challenges of antibiotic resistance and sepsis. The company has been listed under the symbol AXDX on The Nasdaq Stock Market LLC and, according to a Form 25 filed by Nasdaq on July 21, 2025, its common stock was removed from listing and registration on that exchange. An August 8, 2025 Form 8-K notes that the company’s common stock began trading on the OTC Pink marketplace under the symbol AXDXQ after trading was suspended on Nasdaq.

Accelerate Diagnostics focuses on rapid microbiology testing technologies that help clinicians determine optimal antibiotic therapy for serious infections. According to multiple company news releases, its portfolio includes FDA-cleared platforms such as the Accelerate Pheno system and Accelerate PhenoTest® BC kit, as well as the Accelerate Arc™ system and BC kit. These systems are designed to reduce the time required to identify pathogens and determine phenotypic antibiotic susceptibility directly from positive blood cultures.

The Accelerate Pheno system and PhenoTest BC kit combine several technologies to fully automate sample preparation, microbial identification, and phenotypic antibiotic susceptibility testing in approximately seven hours from positive blood cultures. Company disclosures state that external studies have shown this solution can deliver results one to two days faster than existing methods, allowing clinicians to optimize antibiotic selection and dosage for individual patients earlier in the course of treatment.

The Accelerate Arc system and BC kit, which received 510(k) clearance from the U.S. Food and Drug Administration, provide an automated positive blood culture sample preparation platform for use with Bruker’s MALDI Biotyper® CA System and MBT-CA Sepsityper® software extension. Designed for clinical laboratories, the Arc system automates preparation of positive blood culture samples for downstream microbial identification, eliminating the need for overnight culture methods and shortening the time to microbial ID results.

In addition to its cleared systems, Accelerate Diagnostics has been developing the Accelerate WAVE™ system, described in company news as a rapid antimicrobial susceptibility testing (AST) platform. The WAVE system is designed to deliver AST results directly from positive blood culture bottles and bacterial isolate colonies in an average of about 4.5 hours. Company communications describe a user-friendly workflow, high throughput capacity, and a scalable design intended to support a wide range of microbiology laboratory testing demands and hospital formulary needs.

Accelerate Diagnostics reports that the WAVE system uses a workflow intended to enable same-shift targeted antimicrobial therapy for patients with serious infections by providing rapid susceptibility results. The company has disclosed successful pre-clinical trial results for the WAVE system and Gram-negative positive blood culture assay, including performance comparisons to broth microdilution reference methods and high levels of essential and categorical agreement across multiple antibiotic classes.

Across its platforms, the company positions its technology as supporting antimicrobial stewardship efforts by shortening the time to actionable diagnostic information. By providing faster identification and susceptibility data for pathogens causing bloodstream infections, its systems are intended to help clinicians move from broad-spectrum empiric therapy to targeted antimicrobial regimens sooner, which company materials state can improve patient outcomes, reduce hospital costs, and contribute to efforts to combat antimicrobial resistance.

According to repeated descriptions in its press releases, Accelerate Diagnostics operates in the analytical laboratory instrument and in vitro diagnostics space, serving clinical microbiology laboratories and healthcare institutions that manage patients with sepsis and other serious infections. Its systems are designed to integrate into existing laboratory workflows, automate key steps in sample preparation and analysis, and provide results within timeframes that are meaningful for clinical decision-making.

In addition to its diagnostic platforms, the company has referenced proprietary surface coatings technology, OptiChem™, in earlier descriptions of its business. This technology is described as having applications in binding for bio-analytical systems such as microarrays. The company has indicated that it owns and licenses this surface coatings technology alongside its core diagnostic platforms.

Regulatory filings and news releases also highlight that Accelerate Diagnostics has experienced significant financial challenges. A Form 12b-25 filed on August 18, 2025 states that the company and certain subsidiaries filed voluntary Chapter 11 petitions in the United States Bankruptcy Court for the District of Delaware on May 8, 2025. The same filing and a related Form 8-K describe an asset sale process under Section 363 of the Bankruptcy Code and a Chapter 11 Plan of Liquidation. The company has disclosed that, under the confirmed plan, all outstanding shares of its common stock and related equity interests will be canceled and discharged, and holders of those equity interests will not receive or retain any property on account of them.

Through these disclosures, Accelerate Diagnostics presents itself as a specialized diagnostics manufacturer focused on rapid, phenotypic antimicrobial susceptibility testing and automated blood culture workflows, with products designed for clinical laboratories engaged in managing sepsis and antibiotic-resistant infections. At the same time, its SEC filings document a transition through Chapter 11 proceedings, an asset sale to an affiliate of a secured noteholder, and a plan of liquidation that significantly affects existing equity holders.

Business focus and technology

Company materials consistently describe Accelerate Diagnostics as an in vitro diagnostics company dedicated to providing solutions for antibiotic resistance and sepsis. Its Pheno and Arc platforms are FDA-cleared and are designed to automate and accelerate key steps in identifying pathogens and determining their antibiotic susceptibility from positive blood cultures. The WAVE system, as described in news releases, extends this focus by aiming to provide even faster phenotypic AST results with an average time to result of about 4.5 hours.

The company emphasizes automation and time-to-result as central elements of its value proposition. The Pheno system automates sample preparation, identification, and susceptibility testing in a single workflow, while the Arc system automates sample preparation for MALDI-TOF identification. The WAVE system is described as using holographic imaging technology to monitor bacterial growth and morphology changes in real time, although detailed technical specifications beyond those statements are not provided in the supplied materials.

Regulatory and listing status

Accelerate Diagnostics’ common stock was registered under Section 12(b) of the Securities Exchange Act of 1934 and listed on The Nasdaq Stock Market LLC under the symbol AXDX. A Form 25 filed by Nasdaq on July 21, 2025 provides notice of removal of the company’s common stock from listing and registration on Nasdaq. An August 18, 2025 Form 8-K states that, on May 15, 2025, the company’s common stock was suspended from trading on The Nasdaq Capital Market and began trading on the OTC Pink marketplace under the symbol AXDXQ.

The same Form 8-K and the Form 12b-25 filed on August 18, 2025 describe the company’s Chapter 11 cases, the approval of an asset purchase agreement with an affiliate of Indaba Capital Management, L.P., and confirmation of a Chapter 11 Plan of Liquidation. These filings explain that, on the effective date of the plan, all outstanding shares of common stock and related equity interests will be canceled and discharged without recovery for equity holders.

FAQs about Accelerate Diagnostics, Inc. (AXDX)

• What does Accelerate Diagnostics, Inc. do?
  According to its news releases, Accelerate Diagnostics, Inc. is an in vitro diagnostics company dedicated to providing solutions for the global challenges of antibiotic resistance and sepsis. It develops and commercializes platforms such as the Accelerate Pheno system, Accelerate PhenoTest® BC kit, and Accelerate Arc™ system and BC kit, which are designed to automate and accelerate microbial identification and phenotypic antibiotic susceptibility testing from positive blood cultures.
• What are the main products and platforms offered by Accelerate Diagnostics?
  Company disclosures identify several key platforms: the FDA-cleared Accelerate Pheno system and Accelerate PhenoTest BC kit, which automate sample preparation, identification, and phenotypic antibiotic susceptibility testing in approximately seven hours from positive blood cultures; the FDA-cleared Accelerate Arc system and BC kit, which automate positive blood culture sample preparation for use with Bruker’s MALDI Biotyper® CA System; and the Accelerate WAVE™ system, which is described as a rapid antimicrobial susceptibility testing platform designed to deliver results in an average of about 4.5 hours.
• How do Accelerate Diagnostics’ systems aim to impact the management of sepsis and antibiotic resistance?
  In its press releases, the company states that its systems are designed to reduce the time clinicians must wait to determine optimal antibiotic therapy for deadly infections. By providing faster identification and phenotypic susceptibility results directly from positive blood cultures, the platforms are intended to enable earlier targeted antimicrobial therapy, which the company describes as a way to improve patient outcomes, reduce hospital costs, and help combat antimicrobial resistance.
• What is the Accelerate WAVE system?
  According to company announcements, the Accelerate WAVE system is a rapid antimicrobial susceptibility testing system designed to provide AST results directly from positive blood culture bottles and bacterial isolate colonies. It is described as delivering accurate results in an average of about 4.5 hours, with a workflow intended to support same-shift targeted antimicrobial therapy. Company materials also reference successful pre-clinical trial results and ongoing regulatory submissions for this system.
• What is the Accelerate Arc system and how is it used?
  The Accelerate Arc system and BC kit, as described in FDA clearance announcements, are an automated positive blood culture sample preparation platform for use with Bruker’s MALDI Biotyper® CA System and MBT-CA Sepsityper® software extension. The system is designed for clinical laboratories and automates preparation of positive blood culture samples for direct downstream microbial identification, eliminating the need for overnight culture methods and reducing the time to microbial ID results.
• What happened to Accelerate Diagnostics’ Nasdaq listing?
  A Form 25 filed by The Nasdaq Stock Market LLC on July 21, 2025 provides notification of removal of Accelerate Diagnostics, Inc.’s common stock from listing and registration under Section 12(b) of the Securities Exchange Act of 1934. An August 18, 2025 Form 8-K notes that, on May 15, 2025, the company’s common stock was suspended from trading on The Nasdaq Capital Market and began trading on the OTC Pink marketplace under the symbol AXDXQ.
• Did Accelerate Diagnostics file for bankruptcy?
  Yes. A Form 12b-25 filed on August 18, 2025 states that, as reported in a Form 8-K filed on May 8, 2025, Accelerate Diagnostics, Inc. and certain subsidiaries filed voluntary petitions under Chapter 11 of the United States Bankruptcy Code in the United States Bankruptcy Court for the District of Delaware. The filings describe Chapter 11 cases involving an asset sale process and a Chapter 11 Plan of Liquidation.
• What does the Chapter 11 Plan of Liquidation mean for AXDX shareholders?
  The Form 12b-25 and the August 18, 2025 Form 8-K explain that, under the confirmed Chapter 11 Plan of Liquidation, all outstanding shares of common stock of the company, including shares issuable under equity awards and warrants exercisable for common stock, will be canceled and discharged on the plan’s effective date. The filings state that holders of such equity interests will not receive or retain any property on account of those interests.
• Where can investors find more detailed financial information about Accelerate Diagnostics?
  Company news releases indicate that full financial results for specific periods are filed with the U.S. Securities and Exchange Commission on Forms 10-Q and 10-K. The Form 12b-25 filed on August 18, 2025 notes that the company has experienced delays in filing certain periodic reports due to the demands of its Chapter 11 cases and related activities.
• What industry does Accelerate Diagnostics operate in?
  Based on the provided classification and company descriptions, Accelerate Diagnostics operates in analytical laboratory instrument manufacturing and in vitro diagnostics, with a focus on rapid microbiology and antimicrobial susceptibility testing for clinical laboratories managing sepsis and antibiotic-resistant infections.